Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biopharmaceutical

VENDORS EVENT: Somerset County Business Partnership and HINJ to Host ‘How to Do Business with Pharma and Medtech Companies’ on November 2

Bridgewater, NJ, August 6, 2017 — The Somerset County Business Partnership (SCBP) and the HealthCare Institute of New Jersey (HINJ) will host “How to Do Business with Pharma and Medical Technology Companies” on November 2 from 8:00 to 11:30 a.m. at the Raritan Valley Community College, Route 28 and Lamington Road, North Branch.

New Jersey’s biopharmaceutical and medical technology companies purchase more than $6.5 billion worth of goods and services from thousands of local suppliers across the state.

This purchasing power supports more than 350,000 spin-off jobs throughout the state. Continue reading

Partnership Between Drug and Glass Companies Means More Jobs for New Jersey

Vineland, NJ, August 2, 2017 — Bill Gallo, Jr. reported on NJBIZ that a collaborative effort among giants in the pharmaceutical and glass industry will mean new jobs in South Jersey, officials say.

Drug manufacturers Merck and Pfizer have joined with Corning Glass in creating a new, stronger glass packaging for injectable drugs, Valor Glass.

Corporate officials say Corning is making an initial investment of $500 million and creating 1,000 new U.S. jobs as the first part of a planned investment of $4 billion and 4,000 new high-tech jobs. Continue reading

FDA Announces Two Steps to Increase Drug Competition for Improved Patient Access

Washington, DC, August 2, 2017 — The U.S. Food and Drug Administration (FDA) on June 27 announced it is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives.

The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review of generic drug applications where competition is limited.

These actions are among the first taken under the agency’s Drug Competition Action Plan, announced by FDA Commissioner Scott Gottlieb in late May. Continue reading

Choose New Jersey CEO Michele Brown: ‘Access to Lab Space, Funding and Partners Help Biotech Companies Grow in Garden State’

Michele Brown (Photo: NJBIZ/Aaron Houston)

Trenton, NJ, August 1, 2017Choose New Jersey, Inc. led a delegation representing more than 20 New Jersey organizations — including top life sciences companies, universities, trade associations, state officials — as it showcased New Jersey’s assets and resources for biotechnology companies at BIO International 2017, which was June 19-22 in San Diego, California. 

Prior to the BIO event, Choose New Jersey President and Chief Executive Officer Michele Brown in June wrote:

When Hurel Corporation outgrew its incubator space at the Commercialization Center for Innovative Technologies (CCIT) in North Brunswick, New Jersey in 2016, it marked an important milestone for the biotechnology company. Continue reading

U.N. Report: Over Half of People with HIV Having Treatment for First Time

London, July 31, 2017 — The Associated Press’ Maria Cheng reports that that, for the first time in the global AIDS epidemic that has spanned four decades and killed 35 million people, more than half of all those infected with HIV are on drugs to treat the virus, the United Nations said in a report released in Paris on July 20.

AIDS deaths are also now close to half of what they were in 2005, according to the U.N. AIDS agency, although those figures are based on estimates and not actual counts from countries.

Experts applauded the progress, but questioned if the billions spent in the past two decades should have brought more impressive results.  Continue reading

PhRMA Publishes 2017 Biopharmaceutical Industry Resources; Member Companies Spent $65.5 Billion on R&D in 2016

PhRMA’s 2017 “Chart Pack”

Washington, DC, July 28, 2017 — Did you know that Pharmaceutical Research and Manufacturers of America (PhRMA) member companies invested $65.5 billion in research and development (R&D) in 2016?

Or that combined spending on brand medicines, generics and the supply chain account for 14 percent of total national health spending, with brands accounting for just half of this (7 percent)?

Or that the United States accounts for two thirds of the world’s venture capital investments in high-growth biopharmaceutical startups?

These are but a few of the facts that can be found in PhRMA’s 2017 Biopharmaceutical Research Industry Profile and the 152-page industry chart pack, Biopharmaceuticals in Perspective, which were released July 20.
Continue reading

FDA Commissioner Delays Layoff Notices and Reassures Staff Congress Will Reauthorize User Fees

FDA Commissioner Scott Gottlieb, M.D.

Washington, DC, July 27, 2017 — Michael Mezher reports on Endpoints News that, in a July 24 email to agency staff, FDA commissioner Scott Gottlieb, M.D., said he will delay issuing layoff notices until after September 30, which is when the agency’s current user fee agreements expire.

Previously, the FDA indicated it could issue layoff notices to thousands of staffers funded by user fees should Congress not act by August 1.

In the email, Gottlieb said he is optimistic the Senate will take up the matter soon and the agency can “reasonably expect” reauthorization to occur before the September 30 deadline. Continue reading

U.N. Report: Over Half of People with HIV Having Treatment for First Time

London, July 21, 2017 — The Associated Press’ Maria Cheng reports that that, for the first time in the global AIDS epidemic that has spanned four decades and killed 35 million people, more than half of all those infected with HIV are on drugs to treat the virus, the United Nations said in a report released Thursday.

AIDS deaths are also now close to half of what they were in 2005, according to the U.N. AIDS agency, although those figures are based on estimates and not actual counts from countries.

Experts applauded the progress, but questioned if the billions spent in the past two decades should have brought more impressive results. The U.N. report was released in Paris where an AIDS meeting begins this weekend. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, July 19, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, July 18, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading